News & Views | Published:

The myriad targets of a T cell

Nature Biotechnology volume 36, pages 11521154 (2018) | Download Citation

Two methods for measuring cross-reactivity could boost the safety of T-cell therapies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Nat. Rev. Immunol. 12, 669–677 (2012).

  2. 2.

    et al. Cell 157, 1073–1087 (2014).

  3. 3.

    et al. Nat. Biotechnol. 36, 1156–1159 (2018).

  4. 4.

    et al. Nat. Biotechnol. 36, 1191–1196 (2018).

  5. 5.

    et al. Science 274, 94–96 (1996).

  6. 6.

    et al. Nat. Biotechnol. 31, 623–629 (2013).

  7. 7.

    et al. Proc. Natl. Acad. Sci. USA 113, E1890–E1897 (2016).

  8. 8.

    et al. Front. Immunol. 9, 1378 (2018).

  9. 9.

    et al. Nat. Biotechnol. 34, 1037–1045 (2016).

  10. 10.

    et al. Nat. Protoc. 1, 1120–1132 (2006).

Download references

Author information

Affiliations

  1. Aswin Natarajan and Michelle Krogsgaard are in the Department of Pathology and Perlmutter Cancer Center, New York University School of Medicine, New York, New York, USA.

    • Aswin Natarajan
    •  & Michelle Krogsgaard

Authors

  1. Search for Aswin Natarajan in:

  2. Search for Michelle Krogsgaard in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Michelle Krogsgaard.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4309

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing